NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $9,694,261 | +33.9% | 464,507 | -5.7% | 0.00% | +100.0% |
Q1 2024 | $7,242,191 | +148.9% | 492,666 | +74.8% | 0.00% | 0.0% |
Q4 2023 | $2,909,208 | +1.8% | 281,900 | -22.5% | 0.00% | 0.0% |
Q3 2023 | $2,857,314 | -11.4% | 363,526 | +12.7% | 0.00% | 0.0% |
Q2 2023 | $3,223,253 | -32.9% | 322,648 | -40.3% | 0.00% | 0.0% |
Q1 2023 | $4,801,504 | -29.7% | 540,710 | -13.0% | 0.00% | -50.0% |
Q4 2022 | $6,825,695 | +63388.9% | 621,648 | -24.7% | 0.00% | -33.3% |
Q3 2022 | $10,751 | +155.7% | 825,079 | +148.6% | 0.00% | +200.0% |
Q2 2022 | $4,204 | -99.9% | 331,843 | +5.1% | 0.00% | 0.0% |
Q1 2022 | $4,423,000 | -50.5% | 315,666 | +2.3% | 0.00% | -50.0% |
Q4 2021 | $8,931,000 | +139.0% | 308,487 | +147.4% | 0.00% | +100.0% |
Q3 2021 | $3,737,000 | -49.8% | 124,715 | -55.6% | 0.00% | -50.0% |
Q2 2021 | $7,451,000 | -31.0% | 280,852 | -19.1% | 0.00% | -33.3% |
Q1 2021 | $10,791,000 | +105.7% | 347,093 | +117.5% | 0.00% | +200.0% |
Q4 2020 | $5,246,000 | – | 159,549 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |